GlaxoSmithKline PLC
06 February 2006
Issued - Monday 6 February 2006, London
Dr. Moncef Slaoui to Head GlaxoSmithKline Research and Development
GlaxoSmithKline plc (GSK) has announced today that Dr. Moncef Slaoui, currently
Senior Vice President, Worldwide Business Development and External Alliances,
GSK R&D, will become Chairman, Research & Development, effective 1st June 2006.
Reporting to Dr. Jean-Pierre Garnier, Chief Executive Officer of GSK, Dr. Slaoui
will also join the Corporate Executive Team and the company's Board of
Directors.
Dr. Slaoui, 46, will succeed Dr. Tadataka (Tachi) Yamada, who will retire from
the company on 1st June to become Executive Director of the Global Health
Program at the Bill & Melinda Gates Foundation. The retirement of Dr. Yamada is
the subject of a separate announcement today.
Dr. Slaoui will bring to his new role broad experience in scientific research,
product development, and executive management. In his current position, he has
served on the R&D Executive Team and spearheaded recent changes in R&D to
enhance drug discovery and accelerate product development. Previously, in GSK
Biologicals, he engineered the development of a robust vaccines pipeline,
including Rotarix, to prevent infantile gastroenteritis, and Cervarix, to
prevent cervical cancer.
"Moncef combines scientific acumen, sound business sense, and a fervent
commitment to public health," said Dr. Garnier. "Following a career in academia,
he has demonstrated during his 17 years at GSK that he can create a strategic
vision and then vigorously pursue it to develop new products that profoundly
enhance healthcare."
"Moncef is an outstanding scientist and a charismatic leader. Most importantly
he and I share a common commitment to the welfare of patients," said Dr. Yamada.
Dr. Slaoui said, "GSK has one of the most promising pipelines in the industry.
Our challenge, going forward, is to deliver to patients the many medicines we
have in development, whilst continuing to grow the pipeline. Along with my
colleagues in R&D, we are embracing this challenge and we fully expect to be
able to deliver medicines of great value for patients and for GSK in the coming
years."
Dr. Slaoui earned a Ph.D. in Molecular Biology and Immunology from the
Universite Libre de Bruxelles, Belgium, and completed postdoctoral studies at
Harvard Medical School and Tufts University School of Medicine, Boston. He was a
professor of Immunology at the University of Mons, Belgium. He has authored more
than 100 scientific papers and presentations. A citizen of Morocco and Belgium,
he is fluent in English, French, and Arabic.
S M Bicknell
Company Secretary
6 February 2006
Enquiries:
UK Media enquiries: Philip Thomson (020) 8047 5502
David Mawdsley (020) 8047 5502
Chris Hunter-Ward (020) 8047 5502
Alice Hunt (020) 8047 5502
US Media enquiries: Nancy Pekarek (215) 751 7709
Mary Anne Rhyne (919) 483 2839
Patricia Seif (215) 751 7709
European Analyst/Investor enquiries: Duncan Learmouth (020) 8047 5540
Anita Kidgell (020) 8047 5542
Jen Hill (020) 8047 5543
US Analyst/ Investor enquiries: Frank Murdolo (215) 751 7002
Tom Curry (215) 751 5419
This information is provided by RNS
The company news service from the London Stock Exchange
AI Summary Disclaimer BETA
The content you are viewing has been generated or assisted by artificial
intelligence (AI). While efforts are made to ensure accuracy and clarity, AI-generated text may
contain inaccuracies, outdated information, or subjective interpretations. This content is intended
for general informational purposes only and should not be considered professional advice or factual
confirmation.
We encourage you to independently verify any information provided,
especially if it will be relied upon for making decisions or taking action. Any reliance you place
on this material is strictly at your own risk. The AI system that produced this content cannot
assess the specifics of individual circumstances, and results may vary based on context and
individual needs.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.
Create an Account
Create your FREE account to receive personalised announcements, watchlists, market updates, investment insights and new features.
Personalise your experience
Tell us a little about yourself to receive personalised content, announcements and relevant investment opportunities.